Singapore Eye Research Institute, Singapore, Singapore.
Department of Ophthalmology, RWTH Aachen University, Aachen, Germany.
Clin Exp Ophthalmol. 2018 Dec;46(9):1017-1027. doi: 10.1111/ceo.13331. Epub 2018 Jun 27.
To describe long-term outcomes of hemi-automated lamellar keratoplasty (HALK).
HALK is a hybrid anterior lamellar keratoplasty technique for corneas with anterior to mid-stromal scars and topographical irregularities.
Prospective interventional case series.
Thirty-five eyes of 35 consecutive patients undergoing HALK at a single tertiary referral centre from 2007 to 2016.
Patients were followed up for a mean period of 61.4 ± 29.2 months.
Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), spherical equivalent (SE) and cylinder, endothelial cell density (ECD), central corneal thickness (CCT), graft survival and complications were analysed.
The most common indications for HALK were scars because of contact lens associated infectious keratitis (29%), unknown origin (26%) or corneal dystrophies (14%). Five patients had a previous keratoplasty (n = 4; deep anterior lamellar keratoplasty, n = 1). Two HALKs failed at 22 and 32 months follow-up. No graft rejections occurred. UCVA improved from 0.91 ± 0.31 to 0.58 ± 0.35 and BSCVA from 0.66 ± 0.30 to 0.21 ± 0.20 logMAR (P < 0.001) at the last follow-up. Astigmatism (P = 0.2), SE (P = 0.8) and ECD (P = 0.4) did not change significantly during follow-up. CCT increased from 490 to 560 μm (P = 0.004). Kaplan-Meier estimated survival for all HALK cases was 90.6 (95% confidence interval 82.6-98.5) months with a survival probability of 96% at 12 months and 92% at 3, 5 and 7 years of follow-up.
HALK provides excellent graft survival in primary cases and in patients with prior keratoplasty as well as significant improvement in visual acuity with low complication rates.
描述半自动板层角膜移植术(HALK)的长期结果。
HALK 是一种混合式前板层角膜移植技术,适用于从前部到中基质层有瘢痕和地形不规则的角膜。
前瞻性干预性病例系列研究。
2007 年至 2016 年期间,在一家三级转诊中心,35 例连续患者的 35 只眼接受 HALK。
平均随访 61.4±29.2 个月。
未矫正视力(UCVA)、最佳矫正视力(BSCVA)、等效球镜(SE)和散光、内皮细胞密度(ECD)、中央角膜厚度(CCT)、移植物存活率和并发症。
HALK 的最常见适应证是由于接触镜相关感染性角膜炎(29%)、原因不明(26%)或角膜营养不良(14%)所致的瘢痕。5 例患者曾接受过角膜移植(n=4;深板层角膜移植术,n=1)。2 例 HALK 在 22 个月和 32 个月随访时失败。没有发生移植物排斥反应。UCVA 从 0.91±0.31 提高到 0.58±0.35,BCVA 从 0.66±0.30 提高到 0.21±0.20 logMAR(P<0.001)。在随访期间,散光(P=0.2)、SE(P=0.8)和 ECD(P=0.4)没有显著变化。CCT 从 490 增加到 560μm(P=0.004)。Kaplan-Meier 估计所有 HALK 病例的总存活率为 90.6(95%置信区间 82.6-98.5)个月,12 个月时的存活率为 96%,3、5 和 7 年时的存活率分别为 92%。
HALK 在初次手术和先前接受过角膜移植的患者中提供了极好的移植物存活率,同时视力显著提高,并发症发生率低。